Unusual dilemmas of a cardiologist—does congenital absence of the left atrial appendage really mean no indication for oral anticoagulation?

Authors:

Abstract
We present a case of a 72-year-old man with a history of recurrent atrial arrhythmias—paroxysmal atrial fibrillation (AF) and other comorbidities including hypertension, Type 2 diabetes, hypercholesterolaemia, and chronic kidney disease, anticoagulated with rivaroxaban (CHA2DS2-VASc score was 3), in whom several electrical cardioversion (EC) procedures were successfully performed in the past to restore sinus rhythm (SR). Due to the diagnosis of bradycardia-tachycardia syndrome, in April 2022, an atrio-ventricular sequential pacemaker was implanted. Because of the next AF episode exceeding 7 days and temporary break in the use of rivaroxaban anticoagulation, a transoesophageal echocardiography (TEE) before interventional treatment was performed. The examination showed a complete congenital absence of the left atrial appendage (LAA) (Panels E and F). Three-dimensional mapping of the right atrium (RA) was performed, identifying the focus of slowed conduction in the area of the posterior-inferior RA. Radiofrequency ablation of the arrhythmia substrate was performed. During the 3-month follow-up after ablation, the patient had two episodes of AF, each time effectively treated with short-term sedation EC. Despite the lack of LAA, the patient remained on anticoagulation (rivaroxaban) due to still existing strong clinical reasons for long-term anticoagulant treatment, namely three points in CHA2DS2-VASc, left atrium (LA) enlargement, and LA stunning phenomenon after AF reversion to SR. In the meantime, the patient’s myocardial imaging diagnostics was supplemented with a cardiac tomography, during which a congenital isolated absence of the LAA was confirmed (Panels A–D).